An important characteristic of lentiviruses is persistence in infected hosts resulting in progressive or recurrent disease (24, 31, 32 ; W. P. Cheevers and T. C. McGuire, Adv. Virus Res., in press). In hosts with competent immune systems, one mechanism of persistence is restricted lentivirus gene expression in infected cells (3, 11, 27) . Although these infected cells contain the virus genome, they presumably do not make either enough viral proteins to be recognized and destroyed by the immune system or enough virus to infect other cells. However, such latently infected cells do not provide an explanation for recurrence of clinical disease noted with infections by equine infectious anemia virus (EIAV) (19) and caprine arthritis-encephalitis virus (CAEV) (6, 17) . The emergence of virus mutants from latently infected cells which are not recognized by existing neutralizing immune responses could exacerbate disease and enhance persistence by infection of other cells. The occurrence of antigenic variants during infection is documented for EIAV (19, 22) and visna virus (25) and may be a property of all lentiviruses (22, 33) , including human immunodeficiency virus (HIV), which exhibits genetic variation over time (12) .
Initial demonstration of antigenic variation of neutralization-sensitive epitopes of a lentivirus during persistent infection requires that several criteria be met (19, 25) . (i) Infection is initiated with a homogeneous virus population, which may be obtained by a series of terminal dilutions. (ii) The host makes a serum neutralizing antibody response to the infecting virus which is detected in vitro. (iii) Subsequently, virus which is not neutralized by the serum antibody that neutralizes the infecting virus is isolated from the host. Antigenic variation of CAEV, a lentivirus genetically related to EIAV (4) , visna virus (29) , and HIV (4) , has been difficult to study. Previously, neutralizing antibody was not detected in sera of CAEV-infected goats (18, 28) , preventing evaluation of antigenic variation. Hyperimmunization of two CAEV-infected goats with CAEV and Mycobacterium tuberculosis induced serum neutralizing antibody, providing the impetus for further studies (28) . In this report, which confirms the results of a recent report (8) (6, 17) . The CAEV 63 isolate described in previous studies (18) was used either as an uncloned stock (CAEV 63U) or after cloning (CAEV 63C) by three serial terminal dilutions. The origins of the other CAEV isolates (designated Co, 89, and 52) and the two sheep lentiviruses, visna virus and progressive pneumonia virus, have been detailed previously (21) .
Animals and virus infection. All goats were purebred Saanens. The CAEV-infected goats were maintained separately from the CAEV-free goats. Ten goats (group 1) were obtained by cesarean section and infected at 10 days of age with 1.0 ml of 106.2 50% tissue culture infective doses (TCID50s) of CAEV 63C (0.5 ml intravenously and 0.5 ml intra-articularly) (17) . Obtaining goat kids by cesarean section, maintaining those kids isolated from the mother, and feeding them CAEV-free milk prevent most natural transmission from mothers with CAEV (6) . Fifteen goats (group 2) were from CAEV-free mothers and were infected by feeding 10 (17) . Virus isolates from group 1 goats 18, 23, 24, and 51 made at 18, 12, 18, and 9 months p.i., respectively, were used for antigenic variation studies. These virus isolates were made when the carpus was significantly enlarged, indicating active arthritis as previously described (17) . Virus isolates were expanded in synovial membrane cell cultures, and infectivity titers were determined and neutralization assays were done by the virus reduction method described below.
Virus neutralization assays. Two methods were used to determine in vitro serum neutralization of CAEV. The initial detection of serum neutralizing antibodies and all studies except the determination of neutralizing antibody titers were done by a virus reduction method (9) . To determine virus reduction, 0.1 ml of goat serum heated at 56°C for 30 min was added to 0. (30) . To calculate the percent neutralization (reduction), the virus titer determined after incubation with a test serum was subtracted from the mean virus titer (determined after incubation with control serum samples) and the result was divided by the mean virus titer (determined after incubation with control serum samples) and multiplied by 100.
To measure serum neutralization titers, a constant virus and serum dilution method was used (18) . Serum titers were determined twice by using fourfold serum dilutions with four wells per dilution. Input virus of 101-4 to 101.7 was incubated with serum dilutions for 1 h at 37°C. The volumes of reactants and virus detection methods were as described for the virus reduction method.
To demonstrate that the serum neutralizing activity was in the immunoglobulin fraction, immunoglobulin Gl (IgGl) and IgG2 were isolated from two serum samples which neutralized CAEV and from two serum samples from age-matched CAEV-free goats. The IgGl and IgG2, which compose most of the goat serum immunoglobulin, were isolated by ammonium sulfate precipitation and separated on DEAE-cellulose as described previously (14) . Purity of the isolated immunoglobulin fractions was assayed by polyacrylamide gel electrophoresis in sodium dodecyl sulfate, followed by Coomassie brilliant blue staining.
Immunofluorescence assays for p28 were compared with syncytial cell formation to measure CAEV neutralization. A monoclonal antibody to CAEV p28 was used as the first antibody in indirect immunofluorescence assays to detect CAEV infection (21) . The F(ab')2 fragment of rabbit antibodies to mouse immunoglobulins conjugated to fluorescein isothiocyanate (Organon Teknika, Malvern, Pa.) was used as a second antibody.
To determine whether in vitro CAEV neutralization was caused by serum binding to noninfected cells, undiluted serum samples (0.05 ml) were incubated with synovial membrane cells in microdilution wells for 60 min at 37°C. Serum was washed away, and CAEV was titrated on the washed cells as described for the titer reduction assay. RESULTS Table 1 presents results of virus neutralization by serum samples from three groups of goats experimentally infected with CAEV. Of group 1 serum samples, taken 1 year after infection, and group 2 serum samples, taken 2 years after infection, 90 and 46%, respectively, neutralized CAEV 63C used for initial infection (Table 1) . In a previous report (18) , we failed to demonstrate neutralizing activity in serum samples from group 3 goats collected 2 to 39 weeks p.i. with CAEV 63U. Here (Table 1) , serum samples from group 3 goats, taken 36 weeks p.i. failed to neutralize CAEV 63C, confirming our initial observation. However, three of five samples taken 5 years after infection of group 3 goats neutralized CAEV 63C (Table 1) .
Serum neutralization of CAEV blocked both syncytial cell formation and the appearance of viral p28, determined by immunofluorescence assay with monoclonal antibody to p28, indicating that neutralization blocked virus protein production (Table 2 ). IgGl and IgG2 isolated from two neutralizing serum samples contained neutralizing activity, demonstrating that serum neutralization was caused by antibody ( Table 2) . Pretreatment of indicator cells with neutralizing serum before virus titration failed to affect virus titers, ruling out nonspecific blocking of CAEV infection by the binding of antibody to the cell surface ( Table 2) .
Measurement of neutralizing antibody in six goats from group 2 at intervals after infection illustrated its delayed appearance and relatively low titer (Table 3) . Neutralizing antibodies were absent in all six goat serum samples at 3 months, in 50% of the samples at 10 months, and in 33% of the samples at 15 months p.i. All six goats had neutralizing antibodies at 36 months p.i., with titers ranging from 2 to 8. Serum samples from age-matched noninfected goats had no neutralizing activity. The relatively low neutralization titers shown in Table 3 , determined by reaction with 101.4 and 101'7 TCID50s by the constant virus and serum dilution method, are similar to titers observed in some serum neutralization assays of HIV (5, 35) . However, when 104-3 TCID50s of CAEV were incubated with undiluted serum as described for the virus reduction method (9), four low-titer serum samples (.1:2) from group 1 goats reduced the infectivity by as much as 99.9% (Table 4) . Therefore, subsequent serum neutralization experiments were done by the virus reduction method with undiluted serum.
The ungulate lentiviruses are genetically related (29) and have antigenic cross-reactivity of the structural and envelope proteins (10) . To determine whether epitopes recognized by neutralizing antibody are conserved as well, three distinct CAEV isolates and two sheep lentivirus isolates were assayed by using two serum samples from group 2 goats that neutralized CAEV 63C. One serum, G26, clearly failed to neutralize three CAEV isolates and the two sheep lentivirus isolates ( Table 5 ), demonstrating that these isolates do not share neutralizing epitopes recognized by antibodies in G26 serum. The other serum, G14, neutralized the infecting viruses CAEV 63C and CAEV 89 but failed to neutralize the other isolates tested. Variation in epitopes recognized by neutralizing antibody was shown in subsequent joint isolates from four goats (Table 6 ). These antigenic variants were isolated from cellfree synovial fluid aspirated from arthritic carpal joints 9 to 18 months p.i. In each case, serum collected at the same time as or before the joint isolate neutralized the infecting virus (CAEV 63C) but failed to neutralize the subsequent joint isolate. Significant neutralizing antibody against two of the joint isolates (G24 and G51) appeared 3 to 12 months later (Table 6 ). In our previous work (2), the CAEV isolates from G18 and G24 (Table 6) were neutralized by a complementdependent reaction with rabbit antisera to CAEV 63C. These rabbit antisera (2) apparently recognize one or more common neutralization-sensitive epitopes shared by CAEV 63C and the isolates from G18 and G24. In contrast, serum samples from goats infected with CAEV 63C recognize neutralization-sensitive epitopes on CAEV 63C which are not present on G18 or G24 isolates. DISCUSSION This study has defined several characteristics of the neutralizing-antibody response in goats experimentally infected with CAEV. First, infected goats made neutralizing anti- body, although there was individual variation in the response and not all goats responded even 5 years after infection. Second, the initial appearance of neutralizing antibody was delayed for months or years, while an antibody to viral proteins appears within weeks (1). The early appearance of antibodies to CAEV proteins (1) and the lack of functional immunosuppression caused by CAEV infection (7) do not support an immunosuppressive effect of the virus as an explanation for the delay in antibody appearance. Also, peripheral blood mononuclear cell proliferation reactions to CAEV antigen are detectable by 14 days p.i. and increase thereafter (1). Third, neutralizing antibody to CAEV 63C failed to neutralize two ovine lentivirus isolates and generally failed to neutralize CAEV isolates from other goats. The latter result is similar to previous observations made with hyperimmune serum (28) and infected goat serum (8) . Fourth, neutralizing titers against the infecting virus were relatively low and did not always rise progressively during persistent infection (Table 3) (8) . Even though the neutralizing titers were usually low, the reaction is considered specific because it was absent in serum samples from agematched, sham-inoculated, CAEV-free goats and because CAEV-neutralizing serum failed to neutralize other related lentiviruses. Fifth, antigenic variants arose in the synovial fluid of arthritic goats as early as 9 months p.i. In two cases, antigenic variation was followed by the appearance of neutralizing antibody to the new variant. The delayed appearance of neutralizing antibody to infecting virus and to new antigenic variants indicates that the rate-limiting step in the cell-free appearance of antigenic variants of CAEV is the slow development of selective pressure by antibody rather than a slowly mutating virus.
Although antigenic variation occurs in other lentivirus diseases, there are differences in the appearance of the variants during the disease course. Antigenic variants of EIAV are generated as rapidly as 15 days after infection, and at least six variants can appear during the first year after infection (19) . Episodes of clinical disease are associated with the appearance of cell-free antigenic variants in the plasma. In studies with visna virus, antigenic variants were isolated 1 to 3 years after infection and their appearance was used to explain the irregular course of disease in the central nervous system (23, 25, 26) . In two long-term studies, 25% (34) and 16% (20) of the visna virus isolates were antigenic variants, the remainder being similar to infecting virus. These findings were used to argue against the importance of visna virus antigenic variants in the pathogenesis of brain lesions. These observations may result from the method used to isolate the viruses for study; visna virus variants were isolated from peripheral blood cells or cerebrospinal fluid cells by cocultivation with susceptible cells (20, 25, 34) . In vitro cocultivation may activate replication of virus that is restricted in vivo (13) . In contrast, EIAV antigenic variants were isolated from cell-free plasma (19) , and CAEV antigenic variants reported here were isolated from cell-free fluid from joints with active arthritis. Such cell-free virus variants have the potential to infect new pools of cells in vivo and initiate inflammatory processes. With regard to HIV, genetic variation of isolates is extensive (12) , but it is not clear whether HIV antigenic variants will occur and resemble one of the animal lentivirus in their patterns of appearance.
The characteristics of the neutralizing-antibody response and the appearance of antigenic variants may contribute to the recurrence and progression of arthritis seen in a large number of CAEV-infected goats (6, 17) . Joint lesions are characterized by massive accumulations of lymphocytes and macrophages in the synovium (6) . High titers of antibody in synovial fluid to viral antigens, especially gp135 (15) , and a progressive increase in the in vitro proliferative response of peripheral blood lymphocytes to CAEV antigens (1) demonstrate a vigorous immune response to CAEV antigens. The failure of neutralizing antibody to limit infection of susceptible cells during the first few months after infection of the goat could generate a large pool of persistently infected cells. Even if the eventual appearance of neutralizing antibody limits the spread of infecting virus to other cells, the emergence of antigenic variants could keep the infected-cell pool 92.0c G51 (12) 81.7c 999c G51 (18) 99 replenished. Virus which spreads by cell-to-cell contact without neutralization by antibodies, as suggested for visna virus (16) , could also replenish the infected-cell pool. However, a delayed neutralizing antibody response and the development of a number of antigenic variants during persistent disease would be sufficient to provide the continued inflammatory stimuli for progressive arthritis. An alternate possibility is that antigenic variation is an epiphenomenon of lentivirus persistence and has no role in replenishing persistently infected cells. The ability to isolate antigenic variants of CAEV from cell-free synovial fluid provides a lentivirus system to clearly dissect the role of viral antigenic variants in the recurrence and progression of arthritis and in the maintenance of persistently infected cells.
